From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. Pediatrics and Adolescent Medicine>
  4. Summary and Comment

3% Hypertonic Saline for Bronchiolitis

Infants treated with hypertonic saline had outcomes similar to those treated with normal saline.

A recent Cochrane review suggested that 3% hypertonic saline might reduce length of stay in hospitalized infants with bronchiolitis (JW Pediatr Adolesc Med May 13 2009). In a randomized, double-blind clinical trial conducted at a single pediatric emergency department in Canada, 46 infants with bronchiolitis received nebulized racemic epinephrine with either 3% hypertonic saline or normal saline.

Two hours after treatment, no differences were noted between the groups in the two primary outcome measures — change in a reliable and valid measure of respiratory distress and change in oxygen saturation. Fewer infants in the hypertonic saline group than in the control group were admitted to the hospital, but this difference was not statistically significant (35% vs. 57%).

Comment: Bronchiolitis is one of the few pediatric conditions for which hospitalization rates have increased during the past 2 decades. These results will likely prolong the debate about the use of 3% hypertonic saline to treat bronchiolitis. However, in view of recent findings that the combination of nebulized epinephrine and corticosteroids reduces admission rates (JW Emerg Med May 13 2009), we might be on our way to developing effective treatments for bronchiolitis.

Howard Bauchner, MD

Published in Journal Watch Pediatrics and Adolescent Medicine November 25, 2009

Citation(s):

Grewal S et al. A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department. Arch Pediatr Adolesc Med 2009 Nov; 163:1007.

Reader Remarks:

Review and add to remarks on this article

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

The editors of Journal Watch may respond to Reader Remarks, but we cannot promise to respond to a particular remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2009. Massachusetts Medical Society. All rights reserved.